drugset / Trial / NCT05569512
Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying a new drug, uproleselan, to see if it is safe and effective in decreasing relapse after stem cell transplant and improving leukemia-free survival in pediatric patients with acute myeloid leukemia (AML). The name of the study drugs involved in this study are: * Uproleselan * Busulfan * Clofarabine * Fludarabine * Tacrolimus * Methotrexate * Mycophenolate Mofetil
Timeline
- Start
- 2022-10-06
- Primary completion
- 2023-10-05
- Completion
- 2023-12-06
Outcome
Outcome not reported
Stopped: “On 7/26/24 the Sponsor-Investigator was notified GlycoMimetics was terminating contracting for NCT05569512 following company restructuring. This notification came ahead of the study meeting criteria to progress from Phase 1 to Phase 2.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Uproleselan | Small molecule | — | Intravenous |
| Background | Busulfan | Small molecule | — | Intravenous |
| Background | Clofarabine | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |